Testosterone Treatment During Weight Loss: Can your needs change?
As blogged previously, there are many medications that need to be considered for monitoring and...
Read MoreAug 16, 2026 | Uncategorized
As blogged previously, there are many medications that need to be considered for monitoring and...
Read MoreAug 7, 2026 | Media, Uncategorized
Well this is a first in the obesity world. In USA, the FDA has provided guidance to drugmaker Eli...
Read MoreJul 27, 2026 | Media, Uncategorized
As blogged previously, retatrutide is a GLP1, glucagon, and GIP (‘triple G’) agonist...
Read MoreJul 23, 2026 | Media, Uncategorized
There’s a lot of chatter in the virtual space these days about microdosing GLP1 medicines...
Read MoreJul 17, 2026 | Research, Uncategorized
Acquired hypothalamic obesity (AHO) is a rare and particularly challenging form of obesity to...
Read MoreJul 4, 2026 | Media, Uncategorized
Hot on the heels of the first generic Ozempics (semaglutide for type 2 diabetes), the first...
Read MoreJun 28, 2026 | Bariatrics, Uncategorized
Idiopathic intracranial hypertension (IIH) refers to a condition where pressure inside the skull...
Read MoreJun 13, 2026 | Research, Uncategorized
As blogged previously, CagriSema is the first combination treatment of an amylin...
Read MoreJun 11, 2026 | Research, Uncategorized
As blogged previously, retatrutide ( a ‘triple G’ agonist of GLP1, GIP and glucagon)...
Read MoreJun 11, 2026 | Research, Uncategorized
As blogged previously, survodutide is a dual GLP1/glucagon receptor agonist that is being...
Read MoreJun 4, 2026 | Uncategorized
As blogged previously, GLP1 medications [eg semaglutide (Ozempic/Wegovy) , tirzepatide...
Read MoreJun 1, 2026 | Uncategorized
Polycystic ovary syndrome (PCOS) affects 170 million women around the world. The term PCOS is...
Read MoreMay 25, 2026 | Media, Uncategorized
Retatrutide is a ‘triple G’ agonist of the GLP1, glucagon, and GIP receptors. As...
Read MoreMay 18, 2026 | Research, Uncategorized
When people achieve meaningful health benefits and weight loss with weight management medication,...
Read More

I am a medical doctor, Specialist in Endocrinology & Metabolism, a Diplomate of the American Board of Obesity Medicine, and a Clinical Lecturer at the University of Calgary, Canada. After completing my training as an Endocrinologist in 2005 at the University of Calgary, I have worked in Calgary, at the Royal University Hospital in Saskatchewan, and at the University of Copenhagen in Denmark. I have a busy clinical practice at C-ENDO Diabetes and Endocrinology Clinic in Calgary, caring for patients with diabetes, obesity, thyroid, and other hormone issues. I am also involved in clinical research in diabetes and obesity. I am the lead author of the 2020 and 2022 Pharmacotherapy Chapters of the Canadian Obesity Clinical Practice Guidelines, and a member of the Expert Committee for the Diabetes Canada Clinical Practice Guidelines as an author on the Weight Management chapter. I am passionate, enthusiastic, and driven to help conquer the stigma against obesity; educate health care professionals and the public about obesity and diabetes; and to help us become a healthier society!